How is LL-37 administered?
This describes how LL-37 is typically administered in clinical and research references, not a self-administration guide. The usual route is Subcutaneous, on a daily schedule, generally over 4 weeks. Specific dosing is individual and beyond general information, and human evidence for LL-37 is limited.
Administration at a glance (reference data)
- Route: Subcutaneous
- Schedule: Daily
- Cycle length: 4 weeks
- Half-life: ~minutes systemically (longer locally)
References
- LL-37, the truncation product of cathelicidin, antimicrobial review — Wang G, Curr Top Med Chem, 2020
- Human antimicrobial/host defense peptide LL-37 may prevent the spread of a local infection through multiple mechanisms: an update — Svensson D et al., Inflammation Research, 2025
- Significance of the LL-37 Peptide Delivered from Human Cathelicidin in the Pathogenesis, Treatment, and Diagnosis of Sepsis — Mankowska A et al., Archivum Immunologiae et Therapiae Experimentalis, 2025
Pepdex is an editorial reference, not medical advice. Peptides vary in legal and approval status by country, many are research compounds without full human safety data. Talk to a qualified clinician before starting anything.
More on LL-37
Last updated 2026-06-15.